|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LSM14A |
Gene summary for LSM14A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LSM14A | Gene ID | 26065 |
| Gene name | LSM14A mRNA processing body assembly factor | |
| Gene Alias | C19orf13 | |
| Cytomap | 19q13.11 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8ND56 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26065 | LSM14A | C21 | Human | Oral cavity | OSCC | 3.91e-31 | 1.16e+00 | 0.2678 |
| 26065 | LSM14A | C30 | Human | Oral cavity | OSCC | 1.07e-36 | 1.84e+00 | 0.3055 |
| 26065 | LSM14A | C38 | Human | Oral cavity | OSCC | 9.67e-15 | 1.81e+00 | 0.172 |
| 26065 | LSM14A | C43 | Human | Oral cavity | OSCC | 1.83e-39 | 9.24e-01 | 0.1704 |
| 26065 | LSM14A | C46 | Human | Oral cavity | OSCC | 6.25e-21 | 6.51e-01 | 0.1673 |
| 26065 | LSM14A | C51 | Human | Oral cavity | OSCC | 3.79e-12 | 7.68e-01 | 0.2674 |
| 26065 | LSM14A | C57 | Human | Oral cavity | OSCC | 7.99e-12 | 5.07e-01 | 0.1679 |
| 26065 | LSM14A | C06 | Human | Oral cavity | OSCC | 2.06e-04 | 1.40e+00 | 0.2699 |
| 26065 | LSM14A | C07 | Human | Oral cavity | OSCC | 1.34e-02 | 8.71e-01 | 0.2491 |
| 26065 | LSM14A | C08 | Human | Oral cavity | OSCC | 3.00e-35 | 9.59e-01 | 0.1919 |
| 26065 | LSM14A | C09 | Human | Oral cavity | OSCC | 4.69e-10 | 4.85e-01 | 0.1431 |
| 26065 | LSM14A | LN22 | Human | Oral cavity | OSCC | 4.46e-09 | 1.25e+00 | 0.1733 |
| 26065 | LSM14A | LN46 | Human | Oral cavity | OSCC | 8.88e-06 | 6.27e-01 | 0.1666 |
| 26065 | LSM14A | EOLP-1 | Human | Oral cavity | EOLP | 1.41e-06 | 2.98e-01 | -0.0202 |
| 26065 | LSM14A | NEOLP-3 | Human | Oral cavity | NEOLP | 2.76e-04 | 3.27e-01 | -0.0191 |
| 26065 | LSM14A | SYSMH1 | Human | Oral cavity | OSCC | 1.41e-05 | 3.56e-01 | 0.1127 |
| 26065 | LSM14A | SYSMH2 | Human | Oral cavity | OSCC | 8.64e-10 | 6.67e-01 | 0.2326 |
| 26065 | LSM14A | SYSMH3 | Human | Oral cavity | OSCC | 5.81e-17 | 6.50e-01 | 0.2442 |
| 26065 | LSM14A | HTA12-15-2 | Human | Pancreas | PDAC | 1.16e-05 | 5.15e-01 | 0.2315 |
| 26065 | LSM14A | HTA12-26-1 | Human | Pancreas | PDAC | 6.06e-10 | 6.66e-01 | 0.3728 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
| GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
| GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
| GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
| GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
| GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
| GO:00022212 | Cervix | CC | pattern recognition receptor signaling pathway | 39/2311 | 172/18723 | 1.08e-04 | 1.38e-03 | 39 |
| GO:00027534 | Cervix | CC | cytoplasmic pattern recognition receptor signaling pathway | 18/2311 | 60/18723 | 2.26e-04 | 2.55e-03 | 18 |
| GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
| GO:00450882 | Cervix | CC | regulation of innate immune response | 44/2311 | 218/18723 | 6.40e-04 | 5.97e-03 | 44 |
| GO:00395292 | Cervix | CC | RIG-I signaling pathway | 10/2311 | 27/18723 | 9.25e-04 | 7.84e-03 | 10 |
| GO:00028331 | Cervix | CC | positive regulation of response to biotic stimulus | 35/2311 | 168/18723 | 1.23e-03 | 9.87e-03 | 35 |
| GO:00985863 | Cervix | CC | cellular response to virus | 20/2311 | 84/18723 | 2.62e-03 | 1.81e-02 | 20 |
| GO:00395281 | Cervix | CC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 10/2311 | 34/18723 | 6.40e-03 | 3.58e-02 | 10 |
| GO:00019612 | Cervix | CC | positive regulation of cytokine-mediated signaling pathway | 13/2311 | 50/18723 | 6.42e-03 | 3.58e-02 | 13 |
| GO:01400143 | Cervix | CC | mitotic nuclear division | 50/2311 | 287/18723 | 7.27e-03 | 3.91e-02 | 50 |
| GO:00607602 | Cervix | CC | positive regulation of response to cytokine stimulus | 14/2311 | 57/18723 | 8.17e-03 | 4.25e-02 | 14 |
| GO:0045089 | Cervix | CC | positive regulation of innate immune response | 26/2311 | 131/18723 | 9.33e-03 | 4.66e-02 | 26 |
| GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LSM14A | SNV | Missense_Mutation | c.1180N>A | p.Glu394Lys | p.E394K | Q8ND56 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LSM14A | deletion | In_Frame_Del | novel | c.104_118delCCGTAGCCCTTGCCA | p.Thr35_Ala39del | p.T35_A39del | Q8ND56 | protein_coding | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR | ||
| LSM14A | SNV | Missense_Mutation | novel | c.1345N>C | p.Glu449Gln | p.E449Q | Q8ND56 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.584) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| LSM14A | SNV | Missense_Mutation | c.814C>T | p.Arg272Cys | p.R272C | Q8ND56 | protein_coding | tolerated(0.06) | benign(0.051) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| LSM14A | SNV | Missense_Mutation | c.814C>T | p.Arg272Cys | p.R272C | Q8ND56 | protein_coding | tolerated(0.06) | benign(0.051) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| LSM14A | SNV | Missense_Mutation | novel | c.1312C>T | p.Arg438Cys | p.R438C | Q8ND56 | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.648) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LSM14A | SNV | Missense_Mutation | c.580N>G | p.Thr194Ala | p.T194A | Q8ND56 | protein_coding | tolerated(0.1) | benign(0.083) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| LSM14A | SNV | Missense_Mutation | c.814C>T | p.Arg272Cys | p.R272C | Q8ND56 | protein_coding | tolerated(0.06) | benign(0.051) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| LSM14A | SNV | Missense_Mutation | rs377088182 | c.158N>A | p.Arg53His | p.R53H | Q8ND56 | protein_coding | tolerated(0.05) | possibly_damaging(0.76) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
| LSM14A | SNV | Missense_Mutation | c.526C>A | p.Gln176Lys | p.Q176K | Q8ND56 | protein_coding | tolerated(0.06) | benign(0.392) | TCGA-F5-6864-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |